首页> 外国专利> Increased immune response mediated by an antibody-cytokine fusion protein by coadministration with angiogenesis inhibitor

Increased immune response mediated by an antibody-cytokine fusion protein by coadministration with angiogenesis inhibitor

机译:与血管生成抑制剂共同给药可增强抗体-细胞因子融合蛋白介导的免疫应答

摘要

"INCREASED IMMUNE RESPONSE MEDIATED BY AN ANTIBODY-CYTOKIN FUSION PROTEIN BY CO-ADMINISTRATION WITH ANGIOGENESIS INHIBITOR". Compositions and methods for enhancing a cytocidal immune response directed against a cell of the pre-selected type in a mammal are disclosed. The methods and compositions rely on a combination of an anticorpocytokine immunoconjugate and an angiogenesis inhibitor. Once administered to the mammal, the immunoconjugate induces an immune response against the cell of the pre-selected type, for example, a cancer cell that, as a result of synergy with the angiogenesis inhibitor, is greater than the immune response induced by the immunoconjugate. in isolation. The methods and compositions are particularly useful in killing solid tumors or virally infected cells in a mammal.
机译:“通过与血管生成抑制剂的共同管理,增加了由抗体-细胞因子融合蛋白介导的免疫反应”。公开了用于增强针对哺乳动物中针对预选类型的细胞的杀细胞免疫应答的组合物和方法。该方法和组合物依赖于抗细胞因子免疫缀合物和血管生成抑制剂的组合。一旦施用于哺乳动物,免疫缀合物就诱导针对预选类型的细胞的免疫应答,所述癌细胞例如是与血管生成抑制剂协同作用的癌细胞,该免疫应答大于免疫缀合物诱导的免疫应答。 。隔离中。该方法和组合物在杀死哺乳动物的实体瘤或病毒感染的细胞中特别有用。

著录项

  • 公开/公告号BR9909583A

    专利类型

  • 公开/公告日2002-01-15

    原文格式PDF

  • 申请/专利权人 LEXIGEN PHARMACEUTICALS CORP.;

    申请/专利号BR19999909583

  • 发明设计人 STEPHEN D. GILLIES;

    申请日1999-04-15

  • 分类号A61K47/48;A61K38/39;A61K38/46;A61K39/395;A61K38/19;A61K31/405;

  • 国家 BR

  • 入库时间 2022-08-22 00:45:59

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号